Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Pre-existing oncohematological disease (including plasma cell dyscrasia) in kidney transplant recipients does not impact on graft survival, acute rejection, and long-term clinical outcomes.”
Title: Pre-existing oncohematological disease in kidney transplant recipients: impact on graft survival, acute rejection, and long-term clinical outcomes
Authors: Alberto Mella, Roberta Clari, Valeria Deiana, Roberta Giraudi, Gloria Giovinazzo, Ester Gallo, Caterina Dolla, Antonio Lavacca, Ana Maria Manzione, Fabrizio Fop, Anna Allesina, Federica Cavallo, Sara Bringhen, Dario Ferrero, Roberto Mina, Corrado Tarella, Benedetto Bruno, Filippo Mariano, Luigi Biancone
You can read the Full Article on Frontiers in Immunology.
You can find more posts featuring Robert Orlowski on OncoDaily.
